These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36123499)

  • 1. A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects.
    Abouellil A; Bilal M; Taubert M; Fuhr U
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Jan; 396(1):73-82. PubMed ID: 36123499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19.
    Tamura R; Irie K; Nakagawa A; Muroi H; Eto M; Ikesue H; Muroi N; Fukushima S; Tomii K; Hashida T
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):513-521. PubMed ID: 36798006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
    Tempestilli M; Ascoli Bartoli T; Benvenuto D; Stazi GV; Marchioni L; Nicastri E; Agrati C
    J Antimicrob Chemother; 2022 Sep; 77(10):2683-2687. PubMed ID: 35848782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Leegwater E; Moes DJAR; Bosma LBE; Ottens TH; van der Meer IM; van Nieuwkoop C; Wilms EB
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0025422. PubMed ID: 35647646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.
    Avataneo V; de Nicolò A; Cusato J; Antonucci M; Manca A; Palermiti A; Waitt C; Walimbwa S; Lamorde M; di Perri G; D'Avolio A
    J Antimicrob Chemother; 2020 Jul; 75(7):1772-1777. PubMed ID: 32361744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
    Deb S; Reeves AA
    J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
    Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
    J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.
    Alvarez JC; Moine P; Etting I; Annane D; Larabi IA
    Clin Chem Lab Med; 2020 Aug; 58(9):1461-1468. PubMed ID: 32573468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
    Lutz JD; Mathias A; German P; Pikora C; Reddy S; Kirby BJ
    Clin Pharmacol Ther; 2021 Apr; 109(4):1116-1124. PubMed ID: 33501997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
    Cox RM; Wolf JD; Lieber CM; Sourimant J; Lin MJ; Babusis D; DuPont V; Chan J; Barrett KT; Lye D; Kalla R; Chun K; Mackman RL; Ye C; Cihlar T; Martinez-Sobrido L; Greninger AL; Bilello JP; Plemper RK
    Nat Commun; 2021 Nov; 12(1):6415. PubMed ID: 34741049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.
    Corcione S; De Nicolò A; Montrucchio G; Scabini S; Avataneo V; Bonetto C; Mornese Pinna S; Cusato J; Canta F; Urbino R; Di Perri G; Brazzi L; De Rosa FG; D'Avolio A
    Br J Clin Pharmacol; 2021 Dec; 87(12):4861-4867. PubMed ID: 33990984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19.
    Rasmussen HB; Thomsen R; Hansen PR
    Pharmacol Res Perspect; 2022 Apr; 10(2):e00945. PubMed ID: 35396928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase.
    Wang Z; Yang L; Song XQ
    Front Immunol; 2022; 13():1015355. PubMed ID: 36561747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.
    Deb S; Reeves AA; Hopefl R; Bejusca R
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
    Moirangthem DS; Surbala L
    Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.